Insulin Therapy Center

Female, 26 years of age, type 1 diabetes for 15 years, well-educated, uses insulin pump. Recent A1C 7.6%; has been rising from 6 to 6.5. Thinks her mealtime insulin is not working fast enough. She does bolus about 20 minutes before eating. Assessed pump, CGM, food intake and activity. Her report seemed to be the case.

Dr. Stanley Schwartz asks and begins to answer the question: is insulin beneficial for the vasculature as well as the patient -- or not?

Only GLP-1 receptor agonist for use with mealtime or basal insulin for adults with type 2.

Early initiation of therapy hoped to reduce long-term morbidity, mortality by getting to goal earlier; potentially alter the natural history of the disease.

Dr. Israel Hodish talks with Diabetes in Control Publisher Steve Freed at the 2016 ADA Meeting about his ADA presentation on the outcome of patients using insulin and why insulin therapy doesn't work.

Investigation supports that early diabetes has lower thromboembolic risk than later.

Woman, type 1 diabetes, 63 years of age. Well-educated diabetes wise. Reached out to me saying: "HELP!! Normally I take 10 units of Toujeo at 9 pm. I did that last night. This morning I meant to take an additional 2 units because I'm not getting any exercise due to a knee injury. By mistake I took my usual dose of 10 units." Before I read the rest of her email, I thought, I know her. She knows what to do. She wears a CGM, she’ll be watching that. Then I read on...

Man, 63 years of age, type 2 diabetes, obesity, hypertension and hyperlipidemia, referred to me, a CDE, to start him on and teach him how to use insulin. He has had diabetes education in the past, tried lower carb eating and physical activity, but glucose levels still elevated. He told me he felt like a failure. He said he learned he was insulin resistant, made too much insulin, which was causing his co-morbidities. He was very resistant to start insulin, especially since he thought insulin was the cause of his problem.

Study offers at least partial explanation for opposing findings between previous observational studies.

David Kliff, of the Diabetes Investor newsletter, attempts to explain why the cost of insulin is so high and how to solve the problem.